AU2001266575A1 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
AU2001266575A1
AU2001266575A1 AU2001266575A AU6657501A AU2001266575A1 AU 2001266575 A1 AU2001266575 A1 AU 2001266575A1 AU 2001266575 A AU2001266575 A AU 2001266575A AU 6657501 A AU6657501 A AU 6657501A AU 2001266575 A1 AU2001266575 A1 AU 2001266575A1
Authority
AU
Australia
Prior art keywords
chemical compounds
compounds
solvates
salts
structural formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266575A
Inventor
Mark W. Orme
Jason Scott Sawyer
Lisa M. Schultze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Icos LLC
Original Assignee
Lilly Icos LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Icos LLC filed Critical Lilly Icos LLC
Publication of AU2001266575A1 publication Critical patent/AU2001266575A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Abstract

Compounds of the general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.
AU2001266575A 2000-06-26 2001-05-15 Chemical compounds Abandoned AU2001266575A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21428400P 2000-06-26 2000-06-26
US60214284 2000-06-26
PCT/US2001/015550 WO2002000657A2 (en) 2000-06-26 2001-05-15 Condensed pyrazindione derivatives

Publications (1)

Publication Number Publication Date
AU2001266575A1 true AU2001266575A1 (en) 2002-01-08

Family

ID=22798498

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266575A Abandoned AU2001266575A1 (en) 2000-06-26 2001-05-15 Chemical compounds

Country Status (10)

Country Link
US (1) US6903099B2 (en)
EP (1) EP1313736B1 (en)
JP (1) JP2004501919A (en)
AT (1) ATE300543T1 (en)
AU (1) AU2001266575A1 (en)
CA (1) CA2413510C (en)
DE (1) DE60112306T2 (en)
ES (1) ES2247138T3 (en)
MX (1) MXPA02012659A (en)
WO (1) WO2002000657A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
JP4671123B2 (en) 2003-06-23 2011-04-13 小野薬品工業株式会社 New tricyclic heterocyclic compounds
BRPI0506994A (en) 2004-01-22 2007-07-03 Pfizer triazole derivatives that inhibit vasopressin antagonist activity
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
JP5070052B2 (en) 2004-08-17 2012-11-07 ザ・ジョンズ・ホプキンス・ユニバーシティ PDE5 inhibitor composition and method for treating heart disease
JP4997976B2 (en) 2004-12-22 2012-08-15 小野薬品工業株式会社 Tricyclic compounds and uses thereof
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
NZ582772A (en) 2007-07-17 2012-06-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EA031116B1 (en) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг PROPANE-1-SULFONIC ACID {3-[5-(4-CHLORO-PHENYL)-1H-PYRROLO[2,3-b]PYRIDINE-3-CARBONYL]-2,4-DIFLUORO-PHENYL}AMIDE CRYSTALLINE POLYMORPH FORMS
MX2012005284A (en) 2009-11-06 2012-06-28 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor.
AU2011274970C1 (en) 2010-07-06 2015-07-30 Ono Pharmaceutical Co., Ltd. Tetrahydrocarboline derivative
PT2672967T (en) 2011-02-07 2018-12-07 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP3470070B1 (en) 2012-12-21 2021-04-28 Mayo Foundation for Medical Education and Research Methods and materials for treating calcific aortic valve stenosis
EP3191099B1 (en) 2014-09-12 2018-11-14 Biolab Sanus Farmacéutica Ltda Derivatives of pyridopyrimidines
WO2021041539A2 (en) * 2019-08-28 2021-03-04 Ferro Therapeutics, Inc. Compounds and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments

Also Published As

Publication number Publication date
US6903099B2 (en) 2005-06-07
WO2002000657A2 (en) 2002-01-03
US20030181457A1 (en) 2003-09-25
EP1313736A2 (en) 2003-05-28
DE60112306D1 (en) 2005-09-01
DE60112306T2 (en) 2006-01-12
CA2413510A1 (en) 2002-01-03
ATE300543T1 (en) 2005-08-15
ES2247138T3 (en) 2006-03-01
CA2413510C (en) 2007-12-11
MXPA02012659A (en) 2003-09-22
WO2002000657A3 (en) 2002-06-13
EP1313736B1 (en) 2005-07-27
JP2004501919A (en) 2004-01-22

Similar Documents

Publication Publication Date Title
DE60112974D1 (en) Carbolinderivate
AU2001266575A1 (en) Chemical compounds
AU6613896A (en) Chemical compounds
MXPA03002911A (en) Chemical compounds.
MXPA02012076A (en) Chemical compounds.
MXPA03007142A (en) Chemical compounds.
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
NO20025821L (en) 2-aminocarbonyl-9H-purine
GB9801690D0 (en) Therapeutic agents
GB0124933D0 (en) Chemical compounds
MXPA03009750A (en) Chemical compounds.
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
AU2002213419A1 (en) Condensed pyridoindole derivatives
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU7027100A (en) Novel compounds
MXPA02012472A (en) Chemical compounds.
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
CA2445620A1 (en) Tetracyclic compounds as pde5-inhibitors
MXPA03000887A (en) Fused heterocyclic derivatives as phosphodiesterase inhibitors.